CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Elisa-test for IgM and IgG to SARS-CoV-2Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1003 Goal Management Training (GMT) Wiki 1.00
drug1534 Muse headband with Myndlift app Wiki 1.00
drug1173 IgM and IgG diagnostic kits to SARS-CoV-2 Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D003072 Cognition Disorders NIH 0.71
D060825 Cognitive Dysfunction NIH 0.35
D040921 Stress Disorders, Traumatic NIH 0.22
D013313 Stress Disorders, Post-Traumatic NIH 0.20

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001268 Mental deterioration HPO 0.35

There is one clinical trial.

Clinical Trials


1 COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff

During the COVID-19 pandemic several countries have seen a high risk of transmission for health care personnel, with some countries having as many 20-25% of nurses and doctors either infected or showing symptoms of COVID-19. In this prospective cohort study, we will systematically screen all hospital staff in the Capital Region of Denmark for IgM and IgG antibodies against SARS-CoV-2 using a point of care tests and an Elisa kit. Testing will be offered 3 times: In April 2020, Maj 2020 and September 2020. All participants will submit a questionnaire regarding exposures, risk factors and symptoms of COVID-19 in relation to each testing. Follow-up will be through electronic patient records and national registries. We will compare the group of health care personnel with data from a control group of healthy volunteer blood donors from the Danish Blood Donor Study. The aim of the study is to investigate the proportion of hospital staff with SARS-CoV-2 antibodies during the study period compared to a control group representing the Danish population. We will compare the test characteristics of the two methods of testing, a point of care test and Elisa. Further, we will investigate the extent to which prior immunization or infection is protective for future infection with COVID-19.

NCT04346186 COVID Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2 Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2

Primary Outcomes

Description: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population

Measure: Positive IgM/IgG tests

Time: At inclusion

Description: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population

Measure: Positive IgM/IgG tests

Time: 1 month

Description: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population

Measure: Positive IgM/IgG tests

Time: 5 month

Description: Comparison of the resultat from the point of care test and with results from Elisa

Measure: Comparison of the point of care test and Elisa

Time: At inclusion

Description: Comparison of the resultat from the point of care test and with results from Elisa

Measure: Comparison of the point of care test and Elisa

Time: 1 months

Description: Comparison of the resultat from the point of care test and with results from Elisa

Measure: Comparison of the point of care test and Elisa

Time: 5 months

Description: Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19

Measure: Re-infection rate

Time: 180 days

Description: Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19

Measure: Re-infection rate

Time: 360 days

Description: Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up

Measure: IgM/IgG positive participants on follow-up test

Time: 1 month

Description: Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up

Measure: IgM/IgG positive participants on follow-up test

Time: 5 months


No related HPO nodes (Using clinical trials)